Physician profile
Chunlin Yang
NPI 1699878561
$1,880.89
in general payments reported to CMS, 2019-2025
12 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $215 · 2022: $367 · 2023: $429 · 2024: $98.72 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $334.70 | 2019-2020 | |
| Abbvie INC. | $331.06 | 2023 | Vraylar |
| Janssen Biotech, INC. | $238.81 | 2025 | Carvykti, Rybrevant |
| Neurocrine Biosciences, INC. | $206.98 | 2022-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $196.36 | 2022-2023 | |
| Inspire Medical Systems, INC. | $162.41 | 2025 | Inspire |
| Neuronetics, INC. | $113.47 | 2020 | |
| Novo Nordisk INC | $98.16 | 2022 | |
| Lilly USA, LLC | $97.48 | 2025 | |
| Janssen Pharmaceuticals, INC | $61.84 | 2022 | |
| Biotronik INC. | $25.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chunlin Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.